Hereโs Why Cencora (COR) Shares Rose 8% in Q4
๐ Cencora (COR) shares rose 8% following fiscal fourth-quarter earnings that beat consensus estimates.
๐บ๐ธ U.S. business strength offset a miss in international operations during the reported quarter.
๐ผ Management is considering strategic alternatives for animal health and non-core PharmaLex segments.
๐ Hedge fund portfolios holding Cencora increased to 61 at the end of Q4 2025.
๐ฐ Consolidated revenue grew 5.5% year-over-year in fiscal Q1 2026 to reach $85.9 billion.
๐ One-month return for Cencora was -8.13% as of March 19, 2026.
๐ข The company holds a market capitalization of approximately $64.5 billion.
๐ง TimesSquare Capital prefers AI stocks over Cencora for delivering higher returns in shorter timeframes.
Bullish Signals
- Cencora's fiscal fourth-quarter earnings outpaced consensus estimates, demonstrating solid financial performance.
- U.S. business segments provided strength that successfully offset a miss in international operations.
- Consolidated revenue increased 5.5% year-over-year in the first quarter of fiscal 2026 to $85.9 billion.
- Hedge fund interest grew with portfolios holding Cencora rising from 59 to 61 at the end of Q4 2025.
Risk Factors
- Cencora's international business missed consensus estimates during the fiscal fourth quarter.
- The company is considering strategic alternatives for its animal health and non-core PharmaLex segments, indicating potential restructuring or divestiture activity.
- TimesSquare Capital expressed a preference for AI stocks over Cencora regarding higher return potential.
Full Analysis
TimesSquare Capital Management highlighted Cencora (COR) in its fourth-quarter 2025 investor letter, noting an 8% share price gain. The firm cited fiscal Q4 earnings that outpaced consensus estimates, driven by strength in the U.S. market which offset a miss in international business. This positive performance contributed to the stock's broader 24.05% gain over the past 52 weeks.
The investment strategy favors healthcare companies providing novel therapies or specialized services. Regarding Cencora specifically, management announced it is considering strategic alternatives for its animal health and non-core PharmaLex business segments. Despite this, hedge fund portfolios holding Cencora increased to 61 from 59 at the end of the quarter.
In the first quarter of fiscal 2026, Cencora's consolidated revenue rose 5.5% year-over-year to $85.9 billion due to solid growth across both reportable segments. The company has a market capitalization of approximately $64.5 billion. While TimesSquare Capital maintains conviction in certain AI stocks for higher returns, it acknowledges the risk and potential inherent in Cencora as an investment.